카테콜아민 시장 - 유형별, 투여 경로별, 적응증별, 유통 채널별, 세계 예측(2023-2032년)

Catecholamines Market size is estimated to grow at 6.7% CAGR from 2023-2032 attributed to the heightened focus on R&D investments by leading pharmaceutical companies for the development of innovative medications and therapies.

The exploration of novel drug delivery mechanisms, including sustained-release formulations and advanced inhalation therapies is significantly expanding the scope of catecholamine applications. Additionally, the emphasis on precision medicine and the development of targeted therapies tailored to specific patient profiles is fostering the creation of more effective and efficient catecholamine treatments. This continuous innovation is making way for enhanced patient outcomes, further contributing to the overall industry expansion.

The catecholamines industry is categorized into type, route of administration, indication, distribution channel, and region.

Based on type, the market value from the dopamine segment is projected to gain significant traction from 2023 to 2032 due to increasing application of catecholamines in various physiological processes, including cognition, behavior, and motor activity. The ongoing research for revealing the implication of dopamine in neurological disorders, such as Parkinson's disease and schizophrenia is surging the demand for dopamine-based medications and therapies. The escalating efforts spurred by pharmaceutical companies to intensify R&D activities for fostering the development of novel dopamine-targeted treatments and innovative drug delivery mechanisms will also contribute to the segment growth.

In terms of indication, the acute asthma segment accounted for considerable revenue share of the catecholamines market in 2022 and is anticipated to record robust growth up to 2032. This is owing to the rising application of catecholamines in bronchodilation and their effectiveness in managing acute bronchoconstriction. According to the reports published by NCBI in 2023, asthma affects about 300 million people worldwide, leading to significant morbidity and death rate. To that end, the escalating adoption of catecholamine-based bronchodilators, especially in emergency settings will add to the market development.

Regionally, the Asia Pacific catecholamines industry is set to exhibit significant growth through 2032 attributed to the increasing prevalence of cardiovascular diseases and rising healthcare expenditure. According to the Asia Development Bank, one in every four persons in Asia and the Pacific will be beyond the age of 60 years by 2050 driven by longer life spans and lower fertility rates. Additionally, the rapid advancements in healthcare infrastructure is contributing to the growing awareness regarding the benefits of early intervention in cardiovascular ailments. The expanding geriatric population base prone to various cardiovascular conditions will thus support the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data Sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Catecholamines industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Type trends
  • 2.1.4 Indication trends
  • 2.1.5 Route of administration trends
  • 2.1.6 Distribution channel trends

Chapter 3 Catecholamines Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Growing geriatric population
    • 3.2.1.3 Technological advancement in drug delivery system
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and adverse reactions
    • 3.2.2.2 Stringent regulatory framework
• 3.3 Growth potential analysis
  • 3.3.1 By type
  • 3.3.2 By indication
  • 3.3.3 By route of administration
  • 3.3.4 By distribution channel
• 3.4 COVID- 19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Catecholamines Market, By Type, 2018 - 2032 (USD Million)

• 5.1 Key trends, by type
• 5.2 Epinephrine (adrenaline)
• 5.3 Norepinephrine (noradrenaline)
• 5.4 Dopamine

Chapter 6 Catecholamines Market, By Indication, 2018 - 2032 (USD Million)

• 6.1 Key trends, by indication
• 6.2 Anaphylaxis
• 6.3 Cardiac arrest
• 6.4 Shock
• 6.5 Acute asthma
• 6.6 Hypertension
• 6.7 Other indications

Chapter 7 Catecholamines Market, By Route of Administration, 2018 - 2032 (USD Million)

• 7.1 Key trends, by route of administration
• 7.2 Intravenous
• 7.3 Inhalation
• 7.4 Transdermal
• 7.5 Other routes of administration

Chapter 8 Catecholamines Market, By Distribution Channel, 2018 - 2032 (USD Million)

• 8.1 Key trends, by distribution channel
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Catecholamines Market, By Region, 2018 - 2032 (USD Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East & Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East & Africa

Chapter 10 Company Profiles

• 10.1 Pfizer, Inc.
• 10.2 Viatris, Inc.
• 10.3 Novartis International AG
• 10.4 Amneal Pharmaceuticals
• 10.5 Teva Pharmaceutical Industries Ltd
• 10.6 Baxter International
• 10.7 Breckenridge Pharmaceutical, Inc.
• 10.8 Lexicare Pharma Pvt. Ltd
• 10.9 Midas Pharma GmbH
• 10.10 Sun Pharmaceutical Industries Ltd.